Related Experiment Video
Updated: May 18, 2026
07:50
A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|September 7, 2012
Summary
Extended-release naltrexone (XR-NTX) injections effectively treat opioid dependence post-detoxification. Combined with counseling, XR-NTX significantly improves abstinence rates compared to placebo.
Area of Science:
- Pharmacology
- Addiction Medicine
- Clinical Trials
Context:
- Opioid dependence remains a significant public health issue requiring effective long-term treatment strategies.
- Post-detoxification management is crucial to prevent relapse and support sustained recovery.
- Novel therapeutic formulations are needed to improve patient adherence and treatment outcomes.
Purpose:
- To evaluate the efficacy and safety of an extended-release injectable formulation of naltrexone (XR-NTX) for patients with opioid dependence following detoxification.
- To compare the effectiveness of XR-NTX combined with psychosocial treatment against placebo with psychosocial support over a 24-week period.
Summary:
- A 24-week, double-blind, placebo-controlled trial randomized 250 patients with opioid dependence to receive either 380 mg of XR-NTX or placebo, alongside biweekly counseling sessions.
- The primary endpoint, confirmed abstinence from week 5 to 24, was assessed via urine drug tests and self-reporting.
- Secondary endpoints included opioid-free days, craving scores, treatment retention, and relapse rates.
Impact:
- XR-NTX, when administered monthly with psychosocial support, offers a promising new pharmacological option for managing opioid dependence.
- This injectable formulation demonstrated superior efficacy in maintaining abstinence and reducing relapse compared to placebo, highlighting its potential clinical utility.
More Related Videos
09:54Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
Published on: March 8, 2020
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Related Concept Videos
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...